Great to see patient-reported outcomes (#PROs) 🔦at #ASCO24 across symptom science/ pall care + quality of care/ HSR tracks, incl as part of stepped models of care and in large real-world studies 👏👏. Here are my #ASCO24 PRO highlights:

Right on Jill Feldman ! Understanding and mitigating irAEs especially the long term ones that affect quality of life for many people post IO needs to be a high priority area! Jarushka Naidoo Elad Sharon Pauline Funchain Kerry Reynolds Alessio Cortellini Biagio Ricciuti, MD PhD Afreen Shariff, MD

#irAE outcomes needs to be right next to Progression free survival and Disease free survival as a core outcome. Thank you Jill Feldman Rafeh Naqash, MD Elad Sharon Pauline Funchain for amplifying this message. #ASCO24

#irAE Outcomes should be reported right next to progression free survival and disease-free survival outcomes. Thank you Jill Feldman Rafeh Naqash, MD Elad Sharon Pauline Funchain Evan Hall The ASCO Post for amplifying this message. #ASCO24

As the sun sets on #asco24 I’d be remiss not to say that I’m worried about my colleagues I worry we are crushing one another with colossal expectations, with our emails & CVs You are more than your publications & presentations Please don’t tie your self-worth to brass rings

Check out our latest paper on the development of the new EORTC Quality of Life Group (QLG) advanced #melanoma module. Great to contribute 🇦🇺 perspectives from Melanoma Institute Australia. Peter Mac Cancer Centre patients will also be included in Phase 3. #melsm authors.elsevier.com/c/1jFvH3QE--Z9…

I don’t know who else needs to hear this, but I know I did

Heard this today at a funeral and it hit me like a ton of bricks

That Seattle 5k was fantastic! 🤩 We had 122 people race for a cure with us! Thank you to each and every one of you! We are so appreciative of all of your support! 🥇 We were able to raise over $10,000! 👏 👏 👏 And we'd like to thank Fred Hutch Cancer Center for sponsoring this event!

Excited to present ASCO highlights in GU cancers in Scripps Health in Seattle! So much great data to cover! Fred Hutch Cancer Center Shilpa Gupta Uromigos UroToday.com OncoAlert @valdesan Evan Hall @BhatiaS_MD Jessica Hawley MD MS Rahul Banerjee, MD, FACP Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Julie Gralow Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)

Are you interested in how to select side-effects for ePRO symptom monitoring ? We conducted a national modified Delphi to do just that for #immunotherapy side-effects in routine care and found limited coverage of clinically relevant side-effects by existing PROMs JCO Oncology Practice

Find yourself doctors (and colleagues) that get excited about moving the field forward like @alexshoushtari and Allison Betof Warner, MD, PhD Reunion of kindred spirits this morning at Living with Melanoma AIM at Melanoma Foundation and Stanford Cancer Institute

Very proud to be part of multidisciplinary kidney cancer clinic ⁦Fred Hutch Cancer Center⁩ providing 1 stop service for kidney cancer patients⁦Sarah P. Psutka MD MS⁩ ⁦Daniel Lin⁩ ⁦George R Schade⁩ ⁦Evan Hall⁩ ⁦Lisa Tachiki, MD⁩ ⁦Winston Vuong⁩ ⁦Martin Ma⁩

New #JITC article: Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses bit.ly/4dIbUHP @BhatiaS_MD Paul Nghiem

Fantastic work Lisa Tachiki, MD @BhatiaS_MD Fred Hutch Cancer Center et al. Global Oncology at Fred Hutch Dr. Tom Lynch Nicole D. Fleming MD Jessica Hawley MD MS Rahul Banerjee, MD, FACP Evan Hall Beyond Trauma Foundation Binay Shah, MD, MHA MJ UW Medicine Andrew Portuguese Hannah Abrams Natasha Kwendakwema @valdesan OncoAlert Society for Immunotherapy of Cancer

Nice to see this out there! Dr. Silk did a heroic job leading this trial of tvec and nivolumab in rare skin cancers. A collaboration that has spanned many institutions! ⁦Perlmutter Cancer Center at NYU Langone Health⁩ ⁦Dana-Farber⁩ ⁦National Cancer Institute⁩ ⁦Rutgers Cancer Institute⁩

Representing ⁦Fred Hutch Cancer Center⁩ ⁦UW Medicine⁩ ⁦University of Washington School of Medicine⁩ Kidney Cancer Multidisciplinary Team #IKCSNA2024 Kidney Cancer ⁦Sarah P. Psutka MD MS⁩

Fantastic Stanford Department of Medicine Grand Rounds now for the memorial Brooke Gabster, MD lecture Diana Cejas, MD, MPH presents on writing and illness. & some basic neuroanatomy for us internists A special gathering for our community. Our gratitude to Dr. Gabster’s family. medicine.stanford.edu/news/current-n…

The Phase 2/3 Randomized trial of RP2+nivolumab for #uveal #melanoma is now OPEN at Stanford Cancer Institute. This is for patients who have not had prior checkpoint inhibitors or liver-directed therapy. Prior tebentafusp is allowed. The phase 1 data were quite promising and we're excited